Literature DB >> 6268757

Central nervous system vasculitis in cytomegalovirus infection.

A H Koeppen, L S Lansing, S K Peng, R S Smith.   

Abstract

A 51-year-old man received cyclophosphamide, vincristine, procarbazine and prednisone in the treatment of a small-cell undifferentiated lymphoma. Two years later, he developed a rapidly progressive neurological syndrome characterized by a decline in alertness, deafness, blindness and paraplegia. Examination of his eyes revealed severe hemorrhagic chorioretinitis. Leg weakness was thought to be due to transverse myelopathy at a thoracic level. He had a grand mal convulsion and died from terminal bronchopneumonia. Autopsy examination of the eyes revealed sweeping destruction of the retina due to inclusion body chorioretinitis. The brain and spinal cord showed multiple small infarcts accounting for the deafness and paraplegia. The lesions were due to occlusive arteritis in gray and white matter. Veins were also involved. Tissue surrounding the foci of necrosis contained cells with intranuclear an intracytoplasmic inclusion bodies. Some of the Cowdry type A inclusion bodies were large, measuring 30 micrometer in diameter and were located in enlarged cells. Electron microscopy of retina and brain tissue disclosed virus particles compatible with cytomegalovirus. The subject of cerebral and ocular angiitis due to herpes virus infections is reviewed.

Entities:  

Mesh:

Year:  1981        PMID: 6268757     DOI: 10.1016/0022-510x(81)90117-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

1.  Demonstration of perivascular echogenicities in congenital cytomegalovirus infection by colour Doppler imaging.

Authors:  M Ries; K H Deeg; U Heininger
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

Review 2.  Neurology of the vasculitides and connective tissue diseases.

Authors:  P M Moore; B Richardson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

3.  Cerebral venous thrombosis and dual primary infection with human immunodeficiency virus and cytomegalovirus.

Authors:  M C Meyohas; E Roullet; C Rouzioux; A Aymard; B Pelosse; M Eliasceiwicz; J Frottier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

4.  AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients.

Authors:  Y Benhamou; E Caumes; Y Gerosa; J F Cadranel; E Dohin; C Katlama; P Amouyal; J M Canard; N Azar; C Hoang
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

5.  Human immunodeficiency virus-associated cytomegalovirus infection with multiple small vessel cerebral infarcts in the setting of early immune reconstitution.

Authors:  Albert M Anderson; Jack A Fountain; Sonya B Green; Sharon A Bloom; Melody P Palmore
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

6.  Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke.

Authors:  N Edington; C G Bridges; J R Patel
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

7.  Extensive longitudinal myelitis due to cytomegalovirus infection.

Authors:  Rihab Ben Dhia; Mouna Aissi; Mariem Mhiri; Mahbouba Frih Ayed
Journal:  J Neurovirol       Date:  2021-08-27       Impact factor: 2.643

8.  Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS).

Authors:  H Mizusawa; A Hirano; J F Llena; M Shintaku
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

9.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.

Authors:  U R Hengge; N H Brockmeyer; R Malessa; U Ravens; M Goos
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Haemorrhagic conversion of infectious myelitis in an immunocompromised patient.

Authors:  Michael Stephen Pohlen; Jonathan Sunwei Lin; Kevin Yuqi Wang; Mohammad Ghasemi-Rad; Christie M Lincoln
Journal:  BMJ Case Rep       Date:  2017-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.